Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Director departure
Appointed director
ORAMED PHARMACEUTICALS INC. (ORMP) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financi...
Docs: "SECURITIES PURCHASE AGREEMENT",
"EXECUTION VERSION",
"WARRANT NO. ORMP CS-1 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-2 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-3 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-4 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-5 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"Scilex Holding Company Specimen Warrant Certificate",
"Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.",
"Subsidiary Guarantee, by and among Oramed Pharmaceuticals, Acquiom Agency Services LLC, Scilex Holding Company, and certain subsidiaries of Scilex Holding Company party thereto"
08/09/2023 8-K Acquisition/merger/asset purchase announced
Docs: "STOCK PURCHASE AGREEMENT",
"SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION"
08/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Stalking Horse Stock Purchase Term Sheet This term sheet sets forth the principal terms of a proposed equity sale transaction between the parties described herein. Consummation of the Sale is subject to final definitive documentation to be negotiated in good faith between the parties, the satisfaction or waiver of the Closing Conditions set forth below, and authorization and approval by the United States Bankruptcy Court for the Southern District of Texas . This Stalking Horse Term Sheet is solely for discussion purposes and does not purport to summarize all of the terms, conditions, covenants, representations, warranties and other provisions which would be contained in the definitive documentation for the transactions described herein. Seller Sorrento Therapeutics, Inc. Purchaser Oramed P..."
07/13/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/01/2023 8-K Quarterly results
02/27/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "FOURTH AMENDED AND RESTATED BY-LAWS, ADOPTED EFFECTIVE FEBRUARY 23, 2023",
"ARTICLE XVI 11. The Corporation’ s obligation, if any, to indemnify or to advance expenses to any person serving at its request as a director or officer of another corporation, partnership, joint venture, trust or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust or other enterprise. 16 ARTICLE XIV FORUM SELECTION 1. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery and any appellate court thereof shall be the sole and exclusive forum for any derivative action, suit, or proceeding brought on behalf of the Corporation, any action, suit, or proceeding asserting a claim of breach of fiduciary duty owed by an..."
12/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "INVESTOR PRESENTATION DATED DECEMBER 12, 2022"
11/14/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
09/19/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "THIRD AMENDED AND RESTATED BY-LAWS, ADOPTED EFFECTIVE SEPTEMBER 15, 2022",
"ARTICLE V"
09/13/2022 8-K Other Events  Interactive Data
09/08/2022 8-K Other Events  Interactive Data
07/07/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
04/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/28/2022 8-K Quarterly results
01/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Oramed Issues Annual Message to Shareholders"
12/08/2021 8-K Quarterly results
12/07/2021 8-K Quarterly results
11/04/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Engagement Letter, between the Company and H.C. Wainwright & Co., LLC",
"Opinion of Sullivan & Worcester LLP",
"Form of Securities Purchase Agreement, between the Company and each Purchaser in the Offering"
10/29/2021 8-K Other Events
09/01/2021 8-K Quarterly results
08/31/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
08/02/2021 8-K Quarterly results
06/16/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Equity Distribution Agreement, by and between the Company and Canaccord Genuity",
"Opinion of Sullivan & Worcester LLP"
05/25/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/19/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
12/02/2020 8-K Other Events
12/01/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Equity Distribution Agreement, by and between the Company and Canaccord Genuity",
"Opinion of Sullivan & Worcester LLP"
10/22/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentation dated October 22, 2020. (Furnished herewith.)"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy